173 related articles for article (PubMed ID: 15541358)
1. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.
Albanese I; Scibetta AG; Migliavacca M; Russo A; Bazan V; Tomasino RM; Colomba P; Tagliavia M; La Farina M
Biochem Biophys Res Commun; 2004 Dec; 325(3):784-91. PubMed ID: 15541358
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.
Al-Mulla F; Going JJ; Sowden ET; Winter A; Pickford IR; Birnie GD
J Pathol; 1998 Jun; 185(2):130-8. PubMed ID: 9713338
[TBL] [Abstract][Full Text] [Related]
4. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
5. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa.
Visca P; Alò PL; Del Nonno F; Botti C; Trombetta G; Marandino F; Filippi S; Di Tondo U; Donnorso RP
Clin Cancer Res; 1999 Dec; 5(12):4111-8. PubMed ID: 10632348
[TBL] [Abstract][Full Text] [Related]
7. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis.
Chaubert P; Benhattar J; Saraga E; Costa J
Am J Pathol; 1994 Apr; 144(4):767-75. PubMed ID: 8160776
[TBL] [Abstract][Full Text] [Related]
8. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
9. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients.
Conzelmann M; Linnemann U; Berger MR
Int J Oncol; 2004 Jun; 24(6):1537-44. PubMed ID: 15138598
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.
Ikeda S; Shimizu Y; Fujimori M; Ishizaki Y; Kurihara T; Ojima Y; Okajima M; Asahara T
Clin Cancer Res; 2003 Nov; 9(15):5660-5. PubMed ID: 14654549
[TBL] [Abstract][Full Text] [Related]
11. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence.
Kato M; Ito Y; Kobayashi S; Isono K
Cancer; 1996 Apr; 77(8 Suppl):1729-35. PubMed ID: 8608570
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Ki-ras gene mutations within the same tumor using a single tumor crypt in colorectal carcinomas.
Ishii M; Sugai T; Habano W; Nakamura S
J Gastroenterol; 2004 Jun; 39(6):544-9. PubMed ID: 15235871
[TBL] [Abstract][Full Text] [Related]
14. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
15. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
16. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
[TBL] [Abstract][Full Text] [Related]
17. [p53 mutations and protein overexpression in primary colorectal cancer and its liver metastasis].
Yang Y; Xia Q; Lian F
Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):114-8. PubMed ID: 11776850
[TBL] [Abstract][Full Text] [Related]
18. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
[TBL] [Abstract][Full Text] [Related]
19. [Study of the relation between mutant gene in bile and hepatic metastasis of large intestinal carcinoma].
Li S; Yu B; An P; Yuan S; Liang Z
Zhonghua Wai Ke Za Zhi; 1999 Feb; 37(2):106-7. PubMed ID: 11829795
[TBL] [Abstract][Full Text] [Related]
20. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
